PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Early Phase 1 Drug Development Service, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.\', \'Department of Internal Medicine, Clinical Trials Center, Seoul National University Hospital, Seoul, South Korea.\', \'Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.\', \'Department of Clinical Oncology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.\', \'Phase 1 Center, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.\', \'Experimental Cancer Therapeutics Unit, Division of Medical Oncology, National Cancer Centre Singapore, Singapore.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1111/ajco.13510
?:doi
?:hasPublicationType
?:journal
  • Asia-Pacific journal of clinical oncology
is ?:pmid of
?:pmid
?:pmid
  • 33502085
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.58
?:rankingScore_hIndex
  • 20
?:title
  • Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33502085>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33502085>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all